MENU
+Compare
BAYRY
Stock ticker: OTC
AS OF
Feb 21 closing price
Price
$5.76
Change
+$0.02 (+0.35%)
Capitalization
57.55B

BAYRY stock forecast, quote, news & analysis

BAYRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for BAYRY with price predictions
Feb 18, 2025

BAYRY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BAYRY turned positive on February 18, 2025. Looking at past instances where BAYRY's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 14, 2025. You may want to consider a long position or call options on BAYRY as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for BAYRY crossed bullishly above the 50-day moving average on January 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAYRY advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 207 cases where BAYRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BAYRY moved out of overbought territory on January 31, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAYRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BAYRY broke above its upper Bollinger Band on January 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BAYRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.265) is normal, around the industry mean (5.632). P/E Ratio (17.036) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.032) is also within normal values, averaging (3.004). Dividend Yield (0.045) settles around the average of (0.164) among similar stocks. P/S Ratio (1.024) is also within normal values, averaging (3.643).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAYRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

A.I.Advisor
published Dividends

BAYRY paid dividends on May 13, 2024

Bayer A.G. BAYRY Stock Dividends
А dividend of $0.03 per share was paid with a record date of May 13, 2024, and an ex-dividend date of April 29, 2024. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was -10%. AMRN experienced the highest price growth at 16%, while PTKFF experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 20%. For the same stocks of the Industry, the average monthly volume growth was 8% and the average quarterly volume growth was 63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 68
Price Growth Rating: 56
SMR Rating: 60
Profit Risk Rating: 76
Seasonality Score: -50 (-100 ... +100)
View a ticker or compare two or three
BAYRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Kaiser-Wilhelm-Allee 1
Phone
+49 214301
Employees
101369
Web
https://www.bayer.com